Ana Varela-Quiroga

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Correction: Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factors.

Correction: Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factors.

Journal: Frontiers in psychology

Published: March 24, 2026

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 13, 2026

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Journal: Frontiers in immunology

Published: February 02, 2026

From adaptive to maladaptive hippocampal resting-state functional connectivity over the course of multiple sclerosis to understand memory impairment.

From adaptive to maladaptive hippocampal resting-state functional connectivity over the course of multiple sclerosis to understand memory impairment.

Journal: NeuroImage. Clinical

Published: August 08, 2025

Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome.

Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome.

Journal: Frontiers in immunology

Published: August 05, 2025

Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 30, 2025

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis.

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: June 24, 2025

Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis.

Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis.

Journal: Frontiers in immunology

Published: June 17, 2025

Luminex Multiplex Immunoassay for Proteomic Profiling of Cerebrospinal Fluid.

Luminex Multiplex Immunoassay for Proteomic Profiling of Cerebrospinal Fluid.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: April 01, 2025

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 11, 2024

Assessment of clinical prognosis in autoimmune encephalitis: Girona score.

Assessment of clinical prognosis in autoimmune encephalitis: Girona score.

Journal: Frontiers in psychiatry

Published: June 10, 2024

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Journal: Multiple sclerosis and related disorders

Published: April 08, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026